Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities: 2014-2025

Historic Total Current Liabilities for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $26.1 million.

  • Viking Therapeutics' Total Current Liabilities rose 1.49% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 1.49%. This contributed to the annual value of $27.4 million for FY2024, which is 43.26% up from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Total Current Liabilities is $26.1 million, which was down 18.49% from $32.0 million recorded in Q2 2025.
  • Viking Therapeutics' Total Current Liabilities' 5-year high stood at $32.8 million during Q1 2024, with a 5-year trough of $8.8 million in Q4 2021.
  • Over the past 3 years, Viking Therapeutics' median Total Current Liabilities value was $25.1 million (recorded in 2024), while the average stood at $22.8 million.
  • As far as peak fluctuations go, Viking Therapeutics' Total Current Liabilities spiked by 150.02% in 2022, and later tumbled by 40.28% in 2025.
  • Over the past 5 years, Viking Therapeutics' Total Current Liabilities (Quarterly) stood at $8.8 million in 2021, then skyrocketed by 150.02% to $21.9 million in 2022, then dropped by 12.81% to $19.1 million in 2023, then spiked by 43.26% to $27.4 million in 2024, then climbed by 1.49% to $26.1 million in 2025.
  • Its last three reported values are $26.1 million in Q3 2025, $32.0 million for Q2 2025, and $19.6 million during Q1 2025.